Literature DB >> 32968282

Functional genomic landscape of cancer-intrinsic evasion of killing by T cells.

Keith A Lawson1,2,3, Cristovão M Sousa4, Xiaoyu Zhang1,2, Eiru Kim5,6, Rummy Akthar1,2, Joseph J Caumanns1, Yuxi Yao1,2, Nicholas Mikolajewicz1, Catherine Ross1, Kevin R Brown1, Abdelrahman Abou Zid1,7, Zi Peng Fan4, Shirley Hui1, Jordan A Krall4, Donald M Simons4, Chloe J Slater4, Victor De Jesus4, Lujia Tang4, Richa Singh4, Joshua E Goldford4, Sarah Martin4, Qian Huang1, Elizabeth A Francis1, Andrea Habsid1, Ryan Climie1, David Tieu1, Jiarun Wei1, Ren Li8, Amy Hin Yan Tong1, Michael Aregger1, Katherine S Chan1, Hong Han1, Xiaowei Wang1, Patricia Mero1, John H Brumell2,8, Antonio Finelli3, Laurie Ailles9,10, Gary Bader1,2, Gromoslaw A Smolen4,11, Gillian A Kingsbury4, Traver Hart5,6, Charles Kung4, Jason Moffat12,13,14.   

Abstract

The genetic circuits that allow cancer cells to evade destruction by the host immune system remain poorly understood1-3. Here, to identify a phenotypically robust core set of genes and pathways that enable cancer cells to evade killing mediated by cytotoxic T lymphocytes (CTLs), we performed genome-wide CRISPR screens across a panel of genetically diverse mouse cancer cell lines that were cultured in the presence of CTLs. We identify a core set of 182 genes across these mouse cancer models, the individual perturbation of which increases either the sensitivity or the resistance of cancer cells to CTL-mediated toxicity. Systematic exploration of our dataset using genetic co-similarity reveals the hierarchical and coordinated manner in which genes and pathways act in cancer cells to orchestrate their evasion of CTLs, and shows that discrete functional modules that control the interferon response and tumour necrosis factor (TNF)-induced cytotoxicity are dominant sub-phenotypes. Our data establish a central role for genes that were previously identified as negative regulators of the type-II interferon response (for example, Ptpn2, Socs1 and Adar1) in mediating CTL evasion, and show that the lipid-droplet-related gene Fitm2 is required for maintaining cell fitness after exposure to interferon-γ (IFNγ). In addition, we identify the autophagy pathway as a conserved mediator of the evasion of CTLs by cancer cells, and show that this pathway is required to resist cytotoxicity induced by the cytokines IFNγ and TNF. Through the mapping of cytokine- and CTL-based genetic interactions, together with in vivo CRISPR screens, we show how the pleiotropic effects of autophagy control cancer-cell-intrinsic evasion of killing by CTLs and we highlight the importance of these effects within the tumour microenvironment. Collectively, these data expand our knowledge of the genetic circuits that are involved in the evasion of the immune system by cancer cells, and highlight genetic interactions that contribute to phenotypes associated with escape from killing by CTLs.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32968282      PMCID: PMC9014559          DOI: 10.1038/s41586-020-2746-2

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   69.504


  40 in total

1.  Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.

Authors:  Jesse M Zaretsky; Angel Garcia-Diaz; Daniel S Shin; Helena Escuin-Ordinas; Willy Hugo; Siwen Hu-Lieskovan; Davis Y Torrejon; Gabriel Abril-Rodriguez; Salemiz Sandoval; Lucas Barthly; Justin Saco; Blanca Homet Moreno; Riccardo Mezzadra; Bartosz Chmielowski; Kathleen Ruchalski; I Peter Shintaku; Phillip J Sanchez; Cristina Puig-Saus; Grace Cherry; Elizabeth Seja; Xiangju Kong; Jia Pang; Beata Berent-Maoz; Begoña Comin-Anduix; Thomas G Graeber; Paul C Tumeh; Ton N M Schumacher; Roger S Lo; Antoni Ribas
Journal:  N Engl J Med       Date:  2016-07-13       Impact factor: 91.245

2.  A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing.

Authors:  Deng Pan; Aya Kobayashi; Peng Jiang; Lucas Ferrari de Andrade; Rong En Tay; Adrienne M Luoma; Daphne Tsoucas; Xintao Qiu; Klothilda Lim; Prakash Rao; Henry W Long; Guo-Cheng Yuan; John Doench; Myles Brown; X Shirley Liu; Kai W Wucherpfennig
Journal:  Science       Date:  2018-01-04       Impact factor: 47.728

Review 3.  Understanding the tumor immune microenvironment (TIME) for effective therapy.

Authors:  Mikhail Binnewies; Edward W Roberts; Kelly Kersten; Vincent Chan; Douglas F Fearon; Miriam Merad; Lisa M Coussens; Dmitry I Gabrilovich; Suzanne Ostrand-Rosenberg; Catherine C Hedrick; Robert H Vonderheide; Mikael J Pittet; Rakesh K Jain; Weiping Zou; T Kevin Howcroft; Elisa C Woodhouse; Robert A Weinberg; Matthew F Krummel
Journal:  Nat Med       Date:  2018-04-23       Impact factor: 53.440

Review 4.  Elements of cancer immunity and the cancer-immune set point.

Authors:  Daniel S Chen; Ira Mellman
Journal:  Nature       Date:  2017-01-18       Impact factor: 49.962

5.  Identification of essential genes for cancer immunotherapy.

Authors:  Shashank J Patel; Neville E Sanjana; Rigel J Kishton; Arash Eidizadeh; Suman K Vodnala; Maggie Cam; Jared J Gartner; Li Jia; Seth M Steinberg; Tori N Yamamoto; Anand S Merchant; Gautam U Mehta; Anna Chichura; Ophir Shalem; Eric Tran; Robert Eil; Madhusudhanan Sukumar; Eva Perez Guijarro; Chi-Ping Day; Paul Robbins; Steve Feldman; Glenn Merlino; Feng Zhang; Nicholas P Restifo
Journal:  Nature       Date:  2017-08-07       Impact factor: 49.962

6.  Molecular and genetic properties of tumors associated with local immune cytolytic activity.

Authors:  Michael S Rooney; Sachet A Shukla; Catherine J Wu; Gad Getz; Nir Hacohen
Journal:  Cell       Date:  2015-01-15       Impact factor: 41.582

7.  In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target.

Authors:  Robert T Manguso; Hans W Pope; Margaret D Zimmer; Flavian D Brown; Kathleen B Yates; Brian C Miller; Natalie B Collins; Kevin Bi; Martin W LaFleur; Vikram R Juneja; Sarah A Weiss; Jennifer Lo; David E Fisher; Diana Miao; Eliezer Van Allen; David E Root; Arlene H Sharpe; John G Doench; W Nicholas Haining
Journal:  Nature       Date:  2017-07-19       Impact factor: 49.962

8.  Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.

Authors:  Willy Hugo; Jesse M Zaretsky; Lu Sun; Chunying Song; Blanca Homet Moreno; Siwen Hu-Lieskovan; Beata Berent-Maoz; Jia Pang; Bartosz Chmielowski; Grace Cherry; Elizabeth Seja; Shirley Lomeli; Xiangju Kong; Mark C Kelley; Jeffrey A Sosman; Douglas B Johnson; Antoni Ribas; Roger S Lo
Journal:  Cell       Date:  2016-03-17       Impact factor: 41.582

9.  Tumor immune evasion arises through loss of TNF sensitivity.

Authors:  Conor J Kearney; Stephin J Vervoort; Simon J Hogg; Kelly M Ramsbottom; Andrew J Freeman; Najoua Lalaoui; Lizzy Pijpers; Jessica Michie; Kristin K Brown; Deborah A Knight; Vivien Sutton; Paul A Beavis; Ilia Voskoboinik; Phil K Darcy; John Silke; Joseph A Trapani; Ricky W Johnstone; Jane Oliaro
Journal:  Sci Immunol       Date:  2018-05-18

Review 10.  Top 10 Challenges in Cancer Immunotherapy.

Authors:  Priti S Hegde; Daniel S Chen
Journal:  Immunity       Date:  2020-01-14       Impact factor: 31.745

View more
  76 in total

Review 1.  Autophagy in tumour immunity and therapy.

Authors:  Houjun Xia; Douglas R Green; Weiping Zou
Journal:  Nat Rev Cancer       Date:  2021-03-23       Impact factor: 60.716

2.  A comprehensive analysis of different gene classes in pancreatic cancer: SIGLEC15 may be a promising immunotherapeutic target.

Authors:  Ji-Li Xu; Yong Guo
Journal:  Invest New Drugs       Date:  2021-09-13       Impact factor: 3.850

Review 3.  Tumor immunology CRISPR screening: present, past, and future.

Authors:  Matthew B Dong; Kaiyuan Tang; Xiaoyu Zhou; Jingjia J Zhou; Sidi Chen
Journal:  Trends Cancer       Date:  2021-12-15

4.  High FITM2 expression promotes cell migration ability of hepatocellular carcinoma by regulating the formation of caveolae and indicates poor patient survival.

Authors:  Yan Chen; Li-Juan Ji; Yan Wang; Xiang-Feng Guo
Journal:  Histol Histopathol       Date:  2021-10-21       Impact factor: 2.303

Review 5.  Exploring liver cancer biology through functional genetic screens.

Authors:  Cun Wang; Ying Cao; Chen Yang; René Bernards; Wenxin Qin
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-06-23       Impact factor: 46.802

6.  Loss of Optineurin Drives Cancer Immune Evasion via Palmitoylation-Dependent IFNGR1 Lysosomal Sorting and Degradation.

Authors:  Wan Du; Fang Hua; Xiong Li; Jian Zhang; Shasha Li; Weichao Wang; Jiajia Zhou; Weimin Wang; Peng Liao; Yijian Yan; Gaopeng Li; Shuang Wei; Sara Grove; Linda Vatan; Witold Zgodziński; Marek Majewski; Grzegorz Wallner; Haoyan Chen; Ilona Kryczek; Jing-Yuan Fang; Weiping Zou
Journal:  Cancer Discov       Date:  2021-02-24       Impact factor: 39.397

Review 7.  The pleiotropic functions of autophagy in metastasis.

Authors:  Timothy Marsh; Bhairavi Tolani; Jayanta Debnath
Journal:  J Cell Sci       Date:  2021-01-22       Impact factor: 5.285

Review 8.  Synthetic Lethality in Cancer Therapeutics: The Next Generation.

Authors:  Jeremy Setton; Michael Zinda; Nadeem Riaz; Daniel Durocher; Michal Zimmermann; Maria Koehler; Jorge S Reis-Filho; Simon N Powell
Journal:  Cancer Discov       Date:  2021-04-01       Impact factor: 39.397

Review 9.  Genetic and biological hallmarks of colorectal cancer.

Authors:  Jiexi Li; Xingdi Ma; Deepavali Chakravarti; Shabnam Shalapour; Ronald A DePinho
Journal:  Genes Dev       Date:  2021-06       Impact factor: 11.361

Review 10.  Autophagy and tumorigenesis.

Authors:  Michael Rangel; Jerry Kong; Vrushank Bhatt; Khoosheh Khayati; Jessie Yanxiang Guo
Journal:  FEBS J       Date:  2021-07-16       Impact factor: 5.542

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.